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ABSTRACT
Hundreds of small nuclear non-coding RNAs,
including small nucleolar RNAs (snoRNAs), have
been identified in different organisms, with import-
ant implications in regulating gene expression and
in human diseases. However, functionalizing these
nuclear RNAs in mammalian cells remains
challenging, due to methodological difficulties in
depleting these RNAs, especially snoRNAs. Here
we report a convenient and efficient approach to
deplete snoRNA, small Cajal body RNA (scaRNA)
and small nuclear RNA in human and mouse cells
by conventional transfection of chemically modified
antisense oligonucleotides (ASOs) that promote
RNaseH-mediated cleavage of target RNAs. The
levels of all seven tested snoRNA/scaRNAs and
four snRNAs were reduced by 80–95%,
accompanied by impaired endogenous functions of
the target RNAs. ASO-targeting is highly specific,
without affecting expression of the host genes
where snoRNAs are embedded in the introns, nor
affecting the levels of snoRNA isoforms with high
sequence similarities. At least five snoRNAs could
be depleted simultaneously. Importantly, snoRNAs
could be dramatically depleted in mice by system-
atic administration of the ASOs. Together, our
findings provide a convenient and efficient
approach to characterize nuclear non-coding
RNAs in mammalian cells, and to develop antisense
drugs against disease-causing non-coding RNAs.
INTRODUCTION
It has been shown that the majority of the mammalian
genome is transcribed largely as non-coding RNAs
(ncRNAs), whereas only  2% encodes mRNAs (1–3).
These ncRNAs, including miRNAs, small nucleolar
RNAs (snoRNAs), small nuclear RNAs (snRNAs),
Piwi-interacting RNAs and long ncRNAs, are involved
in multiple biological processes, such as DNA and RNA
production, translation and protein translocation, e.g.
(4–5). However, functionalizing individual ncRNAs in
mammals has lagged in time, mainly due to lack of con-
venient knockout or knockdown approaches. This is espe-
cially the case for snoRNAs.
In eukaryotes, several hundred snoRNAs have been
identiﬁed that belong to two major groups: C/D box
and H/ACA box snoRNAs. Most snoRNAs guide nucleo-
tide modiﬁcations in rRNAs, whereas a subset of similar
RNAs are present in Cajal bodies (scaRNAs) and direct
modiﬁcations in snRNAs. In both cases, the C/D box
RNAs guide 20-O-methylation (Nm) and H/ACA RNAs
for pseudouridylation (). The site speciﬁcity of modiﬁca-
tions is provided by base-pairing of a snoRNA/scaRNA
with the substrate RNA(s) (6–8). The mechanisms of
RNA-guided RNA modiﬁcation are conserved in eukary-
otes, and similar machineries also exist in archaea (6,9).
Although yeast snoRNAs have been better characterized
through genetic knockout, the functions of most
snoRNAs in other organisms have not been veriﬁed.
This is particularly problematic since many snoRNAs
are species speciﬁc.
The majority of human snoRNAs were predicted to
guide modiﬁcations in rRNAs and snRNAs, but the pre-
dictions are not experimentally veriﬁed (10). In addition,
even bioinformatics prediction was shown to be difﬁcult,
since no obvious target sites could be found in rRNAs
and snRNAs for many snoRNAs, which are called
orphan snoRNAs. For example,  110 in  360 human
snoRNAs have no potential target sites in rRNAs or
snRNAs (10). These observations raise an interesting pos-
sibility that snoRNAs may have other roles, e.g. in
modulating expression of protein-coding genes. Indeed,
a mammalian brain-speciﬁc snoRNA (HBII52) has been
shown to regulate alternative splicing and/or mRNA
editing (11–13), and miRNAs derived from snoRNAs
have been identiﬁed in human and Giardia lamblia
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already been implicated in human diseases, such as
Prader–Willi Syndrome, Dyskeratosis congenita as well
as cancer (16–19). Thus it is important to functionalize
these ncRNAs, and to be able to manipulate their expres-
sion for therapeutical purpose.
Several features make it difﬁcult to knockout or
knockdown snoRNAs in mammals. First, these RNAs
are highly structured and exist in stable snoRNP
complexes. Each snoRNP contains a unique snoRNA,
and two sets of four core proteins, with Nop56, Nop58,
snu13/15.5K and Nop1/ﬁbrillarin for C/D box snoRNPs
and Nop10, Gar1, Nhp2 and Cbf5/dyskerin for H/ACA
box snoRNPs (6). Second, the gene organizations of
snoRNAs are highly diverged in different organisms
(20). For example, most yeast snoRNAs are independently
transcribed from single copy genes, making it easier for
genetic knockout. In contrast, most mammalian
snoRNAs are encoded in introns of host genes (21),
whereas almost all trypanosome snoRNAs are encoded
in reiterated polycistronic snoRNA clusters (22,23), and
many plant snoRNAs are encoded in intronic or
polycistronic gene clusters (24). Thus, maturation of mam-
malian (and trypanosome and plant) snoRNAs involves
post-transcriptional processing from the host precursor
RNAs (8,25). Additionally, many mammalian snoRNA
genes have multi-copies or isoforms (10), adding more
obstacles for genetic manipulation of snoRNAs.
Several attempts have been made to knock down
snoRNAs. In trypanosomes, it has been shown that
over-expression of antisense RNA or double-stranded
RNA was able to degrade snoRNAs, yet not all tested
snoRNAs were depleted (26,27). The working system for
studying vertebrate snoRNAs is Xenopus oocyte, where
antisense oligonucleotides (ASOs) were microinjected
into nucleus to knockdown snoRNA (28). However, this
approach cannot fulﬁll the functional study for mamma-
lian snoRNAs, since many snoRNAs are species speciﬁc.
In addition, other approaches have been attempted to
knockdown mammalian snoRNAs, including siRNA,
ribozyme, locked nucleic acid (LNA) and peptide–
nucleic-acid oligonucleotides. In no case was the
function of the targeted snoRNA disrupted, albeit one
tested snoRNA (U81) was reduced by  60% using LNA
or ribozyme (29), suggesting that a more efﬁcient deple-
tion approach is required for functional analysis. During
our study, a recent work was published showing that
snoRNAs could be depleted in human cells by
20-methyloxylethyl modiﬁed (20-MOE), phosphorothioate
backbone-containing RNA–DNA chimeric ASOs (30).
However, delivery of ASOs was performed in that study
using electroporation with a specialized device
(nucleofection), making it difﬁcult to judge if ASOs
could be delivered to the nucleus in animals by systematic
administration and used as drugs to target disease-causing
nuclear ncRNAs. In addition, it is also not clear if such an
approach is suitable for functionalization of snoRNAs,
since most mammalian snoRNAs are encoded in introns
of host RNAs, which, in principle, can also be targeted to
degradation by the ASOs.
In this study, we determined if snoRNAs could be efﬁ-
ciently depleted by our 20-MOE/chimeric ASOs using con-
ventional transfection in human and mouse cells. These
ASOs can efﬁciently and speciﬁcally deplete mRNAs
through an RNaseH1-based mechanism and exhibit high
afﬁnity to RNA (31). Our strategy includes full-length
screening of ncRNAs to map RNA accessible sites with
these ASOs, and using selective reduction of ncRNAs to
investigate functional changes of targeted RNAs. We
found that all tested snoRNAs and snRNAs could be dra-
matically depleted with high speciﬁcity, and that depletion
of intronic snoRNAs does not affect expression of the
host genes. We used this method to evaluate the
proposed functions of several snoRNAs. Importantly,
we also demonstrated that snoRNAs can be dramatically
depleted in mice by administration of ASOs.
MATERIALS AND METHODS
Oligonucleotides
Synthesis of RNA/DNA chimeric phosphorothioate/
20-O-MOE oligonucleotides was carried out as described
previously (32). Unless indicated, all ASOs used for tar-
geting snoRNAs were 5–10–5 RNA/DNA chimeric oligo-
nucleotides linked with phosphorothioate backbone, with
10 deoxyribonucleotides ﬂanked by 5 20-O-MOE modiﬁed
ribonucleotides at both sides. DNA oligonucleotide
probes used for northern hybridization, primer extension
and quantitative real time PCR (qRT-PCR) are listed in
Supplementary Data.
Cell growth and ASO transfection
HeLa cells were grown on plates in DMEM medium sup-
plemented with 10% fetal calf serum (FCS) and 1% peni-
cillin/streptomycin at 37 Ci n5 %C O 2 incubator. For
knock-down of targeted snoRNA genes, sub-conﬂuent
cells ( 30–50%) were treated with ASOs at a 50nM
ﬁnal concentration (or as indicated) in Opti-MEM
medium containing 4mg/ml Lipofectamine 2000
(Invitrogen) for 4 h, based on the manufacturer’s instruc-
tion. Four hours after transfection, medium was replaced
with DMEM medium supplemented with 10% FCS and
1% penicillin/streptomycin. For ASO screening, transfec-
tion was performed in six-well dishes. For other experi-
ments, transfection was carried out in 75cm
2 dishes. Cells
were harvested 48h after transfection, or at different time
points as indicated in ﬁgure legends. For multiple
snoRNA depletion, ASOs targeting different snoRNAs
were co-transfected, at ﬁnal concentrations described in
ﬁgure legends.
Northern hybridization and qRT-PCR
Total RNA was prepared using Tri-Reagent (Sigma),
based on the manufacturer’s instructions. Five microgram
total RNA was separated in 8% polyacrylamide–7M urea
gels and was transferred onto membrane, using semi-dry
transfer apparatus. Northern hybridization was per-
formed using 50-end-labeled oligonucleotide probes, as
described previously (33). Real-time PCR (qRT-PCR)
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sentially as described (32). A forward primer T7F2
(50 tacttaatacgactcactataggctagcctcg 30) that is speciﬁc to
a mini-reporter gene derived from exons 6–8 of SMN2
pre-mRNA and a reverse primer SMN-E6/7R (50 TTTT
GTCTAAAACCCATATAATAGCC 30) were used to
detect spliced mRNA, using SMN-E6P (6FAM-CAGAT
TCTCTTGATGATGCTGATGCTTTGG-IABkFQ) as a
probe. Another reverse primer SMN-I6R (50 TGTCAGG
AAAAGATGCTGAGTG 30) was used in combination
with T7F2 and SMN-E6P to detect un-spliced
pre-mRNA (T. A. Vickers et al., manuscript in
preparation).
Detection of 20-O-methylations
Methylation was determined by primer extension assay
using two different dNTP concentrations (0.05 and
5mM), as described previously (34). Primer extension
sequencing reaction was performed as in (35). Extension
products were separated in 8% polyacrylamide–7M urea
gels. For quantitative analysis of 20-O-methylation, RNase
H-cleavage assay was performed (36). Brieﬂy, 2ml( 4 mg)
total RNA was hybridized with 3ml (300pM) chimeric
oligonucleotide (XL086) by heating at 90 C for 5min,
incubated at 37 C for 10min and cooled on ice for
2min. Next, 5ml2   RNase H buffer (40M Tris.Cl pH
7.5; 20mM MgCl2; 200mM KCl; 50mM DTT; 10%
sucrose) containing 3 units of RNase H (NEB) and 2
units of RNase Inhibitor (NEB) were added. The RNA
was digested at 37 C for 60min, separated in a 1.2%
agarose gel and transferred onto a membrane. 18S
rRNA and its 50 cleaved product were detected by
northern hybridization using a 50-end-labeled probe.
Analysis of pseudouridines
Total RNA was treated with CMC, and pseudouridines
were detected by primer extension assay using
50-end-labeled primers downstream to the pseudouridine
sites, as described previously (37).
Chemical probing of snoRNA structure
Preparation of HeLa cell nucleus and chemical modiﬁca-
tion with dimethylsulfate (DMS) were performed essen-
tially as described (38), except that nuclei were incubated
with DMS at a 3% ﬁnal concentration for 5min at room
temperature (RT), and total nuclear RNA was prepared
using Tri-Reagent. Primer extension was performed using
10mg nuclear RNA and a 50-end-labeled oligonucleotide
speciﬁc to U16 snoRNA.
Western blotting
Whole cell lysate was separated in 4–12% gradient
SDS–PAGE gels. Proteins were transferred to PVDF
membrane for 1h using a semi-dry transfer apparatus at
25V constant. The membranes were blocked for 1h with
block buffer (5% dry milk in 1  TBS), and incubated with
primary antibodies against RPL4 (11302-1-AP,
Proteintech, 1:1500), alpha-tubulin (T-5168, Sigma,
1:8000) or Nucleolin (ab22758, Abcam, 1:2000) at RT
for 3–4 h. After three washes with wash buffer (1  TBS,
0.1% Tween-20), membranes were incubated with
anti-rabbit or anti-mouse secondary antibody at RT for
1 h. After three washes, proteins were detected using ECL
(Abcam).
Immunoﬂuorescence
HeLa cells grown in glass-bottom dishes (MEK) were
transfected using Lipofectamine 2000 with 50nM of dif-
ferent oligonucleotides and incubated for 6h at 37 Ci na
5% CO2 incubator. Cells were washed three times with 1 
PBS, ﬁxed at RT for 30min with 4% formaldehyde and
permeabilized for 5min with 0.1% Triton-100 in 1  PBS.
After 30min blocking with block buffer (1mg/ml BSA in
1  PBS), cells were incubated for 4h with block buffer
containing an rabbit polyclonal antibody (6653) that rec-
ognizes phosphorothioate backbone containing oligo-
nucleotides (1:200, a gift from Erich Koller) and a
mouse monoclonal antibody for nucleolin (1:400,
ab13541, Abcam). After three washes (5min each) with
wash buffer (0.1% tween-20 in 1 PBS), cells were
incubated for 1h with block buffer containing secondary
antibodies against rabbit (ab6717, Abcam, conjugated
with FITC; 1:400) and mouse (ab6563, Abcam,
conjugated with Cy5; 1:400) IgG. After three washes,
anti-fade solution was added and the slides were
covered. Cells were imaged with a confocal microscope
(Olympus, Fluoview 1000) and images were processed
using software FV10-ASW 2.1.
RESULTS
U16 snoRNA can be dramatically depleted by 20-MOE/
chimeric ASOs using conventional transfection in different
human cells
To determine if the 20-MOE/chimeric ASOs are able to
reduce snoRNAs through conventional transfection, we
initially targeted U16, a C/D box snoRNA. Twenty
seven ASOs were synthesized that cover the entire coding
region and adjacent ﬂanking sequences of U16 snoRNA
(Figure 1A and Supplementary Figure S1A). Each ASO
contains 20 nts linked by Phosphorothioate backbone,
with 10 deoxyribonucleotides in the middle ﬂanked at
both ends by 5 ribonucleotides containing 20-MOE modi-
ﬁcation (Supplementary Figure S1B). HeLa cells were
transfected using Lipofectamine 2000 (Invitrogen) with in-
dividual ASOs at 50nM ﬁnal concentration. The effects of
ASO treatment on U16 snoRNA level were determined by
northern hybridization. Two ASOs (462025 and 462026)
reduced U16 snoRNA by >90%, and moderate reduction
( 40–50%) was found with two neighboring ASOs
(462027–462028) (Figure 1A). However, most other
ASOs, including those targeting the ﬂanking sequences,
had no or little effects.
Since snoRNAs are structured and assembled in RNP
complexes, the different effects of ASOs on snoRNA re-
duction may be related to the accessibility of the snoRNA
regions to the ASOs. Indeed, we found that the U16
snoRNA regions targeted by the two most active and
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in vivo, as determined by chemical structure probing
using DMS, which modiﬁes accessible A and C nucleo-
tides. The snoRNA regions (U32–U66) targeted by
ASO462025–ASO462028 are clearly modiﬁed by DMS
(Figure 1B and C), suggesting that, as expected, the
knockdown efﬁciency of ASOs correlates with the acces-
sibility of the binding sites in the snoRNP.
In addition to HeLa cells, U16 snoRNA could also be
dramatically depleted in HEK-293 or A549 cells, by trans-
fection of ASO462026 (50nM) using Lipofectamine 2000
(Figure 2A), indicating that ASOs can knock down U16
RNA in different cell types, by conventional transfection.
In fact, dramatic reduction of U16 snoRNA could also be
achieved using different transfection reagents. More than
90% reduction was achieved using RNAiMax, similar to
Figure 1. A C/D box snoRNA U16 can be speciﬁcally depleted by 20-MOE/chimeric ASOs. (A) Identiﬁcation of the active ASOs by full RNA
screening. HeLa cells were treated with 50nM ASOs targeting different regions of the U16 snoRNA for 48 h, and total RNA was prepared and
subjected to northern hybridization using a 50-end-labeled oligonucleotide probe speciﬁc to U16 snoRNA. U4 snRNA was detected and served as a
loading control. The ASOs causing highest reduction in U16 snoRNA levels are boxed. UTC, untreated cells. Lower panel depicts U16 snoRNA
regions targeted by the ASOs. The gray box, white box and thin line represent the coding region, the junctions between the coding region and
ﬂanking sequence and ﬂanking sequence, respectively. (B) Structure probing for U16 snoRNA. Nuclei were prepared from HeLa cells and incubated
with (+) or without (–) 3% DMS at RT for 5min. RNA was prepared and subjected to primer extension using a 50-labeled primer speciﬁc to U16
snoRNA. Extension products were analyzed in an 8% polyacrylamide, 7M urea gel, next to a DNA sequencing ladder generated with the same
primer. The nucleotides accessible to DMS are identiﬁed. (C) Proposed secondary structure of U16 snoRNA. The structure was predicted using
program mFold (http://mfold.bioinfo.rpi.edu/cgi-bin/rna-form1.cgi), and reﬁned based on the probing data in (B). The accessible nucleotides are
marked with arrowheads. The C and D motifs are boxed. The nucleotides complementary to rRNA for guiding modiﬁcation are circled. The
sequences targeted by the active ASOs (462025 and 462026) are marked by lines.
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with Oligofectamine (Figure 2B and C). Interestingly,
pre-assembly of the ASOs with the transfection reagent
did not increase the level of snoRNA reduction, as
compared with transfection of non-assembled ASOs.
The following studies were performed in HeLa cells
using Lipofectamine 2000 as transfection reagent, unless
indicated.
Figure 2. 20-MOE/chimeric ASOs operates in different human cells to deplete U16 snoRNA and are more effective than other types of oligonucleo-
tides. (A) Three different types of human cells were treated with (+) or without (–) 50nM of ASO462026 for 48 h, and levels of U16 snoRNA were
determined by northern hybridization. U80 snoRNA was detected and served as a loading control. (B) U16 snoRNA was depleted in HeLa cells by
ASO462026 treatment using different transfection reagents. Total RNA was prepared 24 h after transfection, and analyzed by northern hybridization
using probes speciﬁc to U16 and U80 snoRNAs. 2000, Lipofectamine 2000; Oligo, Oligofectamine; RNAiMax, Lipofectamine RNAiMax
(Invitrogen). Free: transfection was performed by adding 4mg/ml (Lipofectamine 2000 and Oligofectamine) or 6mg/ml (Lipofectamine RNAiMax)
reagents into culturing medium (Opti-MEM, Invitrogen), followed by addition of the U16 ASO to a ﬁnal concentration of 50nM. Pre: ASOs were
pre-mixed with transfection reagent, and the mixture was incubated at room temperature for 10min, followed by addition to the culturing medium
(Opti-MEM). UTC, untreated cells. (C) The U16 levels detected in (B) were quantiﬁed using ImageJ and normalized to the level of U80 snoRNA.
The relative levels were plotted and indicated. The transfection reagents were as described in (B). F, free transfection; P, pre-assembled. (D) HeLa
cells were treated for 48 h with different concentrations of ASO462026, or a DNA oligonucleotide linked with phosphorothioate backbone that has
the same sequence as ASO462026 (E), or siRNA with the same sequence (F). The level of U16 snoRNA was determined by northern hybridization.
5.8S and 5S rRNAs are shown as ethidium bromide staining of the gel. (G) HeLa cells were treated for 48 h with 50nM of either 20-MOE/chimeric
ASOs (ASO) or 20-MOE modiﬁed, phosphorothioate linked RNA oligonucleotides with the same sequences (RNA) as ASOs. Total RNA was
prepared and subjected to northern hybridization, as in (A). U80 snoRNA served as a loading control.
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depleting U16 snoRNA, a DNA oligonucleotide linked
with phosphorothioate backbone with the same sequence
as ASO462026 has little effect. For example, at 50nM
concentration, >90% reduction of U61 snoRNA was
obtained with the 20-MOE/chimeric ASO (Figure 2D),
yet only  30% reduction was found for the DNA oligo-
nucleotide transfected in the same way (Figure 2E). In
addition, treatment with siRNA containing the
ASO462026 sequence did not decrease the level of U16
snoRNA (Figure 2F), supporting the previous observation
(29). Consistent with the possibility that the ASOs deplete
U16 snoRNA through an RNaseH-based mechanism,
uniform 20-MOE/RNA oligonucleotides with the same se-
quences as ASO462025 or ASO462026 could not reduce
U16 snoRNA (Figure 2G). Together, these results indicate
that the 20-MOE/chimeric ASOs can efﬁciently reduce
U16 snoRNA using conventional transfection, in various
cell types.
Depletion of U16 snoRNA impaired its function in
guiding rRNA modiﬁcation
As U16 snoRNA was postulated to guide
20-O-methylation at position A484 of 18S rRNA (39),
we determined if depletion of U16 snoRNA reduced the
methylation level at the predicted site. HeLa cells were
treated with different ASOs, and total RNA was
prepared 48h after transfection. As expected,
ASO462025 and ASO462026 reduced U16 snoRNA by
 90%, whereas ASO462027 led to a  65% decrease
(Figure 3A). The 20-O-methylation was determined using
a primer extension assay, in which methylated nucleotides
cause extension to stop one nucleotide before the methy-
lation sites at low but not high dNTP concentration (34).
Indeed, dramatic depletion of U16 snoRNA by
ASO462025 and 462026 caused  70% reduction in the
signal strength of primer extension stop at Am484 site
(Figure 3B), but not at a neighboring methylation site
(Am468). In contrast, moderate reduction of U16
snoRNA by ASO462027 only led to a slight decrease
( 15%) in the methylation signal, consistent with the
previous ﬁnding that a 60% reduction of a snoRNA
(U81) did not impair its guide function (29).
To further conﬁrm the methylation reduction at
position A484 of 18S rRNA, we employed a more quan-
titative approach, an oligonucleotide directed, site-speciﬁc
RNaseH cleavage assay (36), in which only the 18S rRNA
lacking A484 methylation could be cleaved. Total RNA
was incubated with a DNA/RNA chimeric oligonucleo-
tide speciﬁc to the A484 region, digested by RNase H,
and 18S rRNA was probed by northern hybridization.
Approximately 55% of 18S rRNA from U16 depleted
cells was cleaved, whereas no rRNA cleavage was found
for control cells (Figure 3C), indicating that depletion of
U16 indeed reduced the level of A484 methylation. The
incomplete loss of A484 modiﬁcation may stem either
from the long half-life of mammalian rRNAs ( 3–7
days) (40), or from the remaining enzymatic activity of
the residues U16 snoRNP. Nevertheless, these results
indicate that ASO-mediated depletion of U16 snoRNA
speciﬁcally reduced the methylation guided by this
snoRNA, and that the predicted function of this RNA
could be conﬁrmed.
Since rRNAs have a long half-life, signiﬁcant reduction
of methylation is expected to appear at a time point later
than depletion of the snoRNA. To determine the kinetics
of snoRNA and methylation reduction, HeLa cells were
treated with ASO462026 for different times, and the levels
Figure 3. Depletion of U16 snoRNA impairs its function in guiding
20-O-methylation. (A) U16 snoRNA was depleted to different extents
by treatment with different ASOs (462025, 462026 or 462027) in HeLa
cells for 48 h, as determined by northern analysis. Ethidium bromide
staining of 5S rRNA is shown in the lower panel. (B) The same total
RNA as used in (A) was subjected to primer extension analysis using a
primer speciﬁc to 18S rRNA, to determine the methylation status at
the predicted site (A484). Extension products were separated in an 8%
polyacrylamide gel. The targeted Am484 is indicated with an arrow,
whereas an adjacent methylation (Am468) is marked with an arrow-
head. m, 20-O-methylation. (C) Methylation reduction at site A484 was
conﬁrmed by an RNase H-cleavage assay. Total RNA was annealed
with a DNA–RNA chimeric oligonucleotide complementary to A484
region of 18S rRNA, followed by digestion using E. coli RNaseH. The
digested products were analyzed by northern hybridization using a
probe speciﬁc to 18S rRNA, upstream to A484 site. The cleaved
fragment representing unmodiﬁed 18S rRNA is marked with an
arrow. U3 snoRNA served as a loading control. (D) Time course of
U16 snoRNA depletion by ASO treatment. HeLa cells were transfected
with 50nM ASO462026 for different times, as indicated above lanes.
Total RNA was prepared and the level of U16 was analyzed by
northern hybridization. U23 was probed and used as a loading
control. (E) Quantiﬁcation of U16 snoRNA as detected in (D), and
normalized to U23 snoRNA. (F) Methylation reduction at A484 was
apparent at later time points. Total RNA as used in (D) was subjected
to primer extension analysis to detect the levels of methylation, as in
(B). Methylation at site A468 was shown as a control.
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were analyzed. Although U16 snoRNA was reduced to a
maximum extent within 12h (as early as 4 h) after trans-
fection (Figure 3D and E, and data not shown), strong
reduction in the methylation level was only detected at
48h and after (Figure 3F). Note that reduction of U16
snoRNA maintained for at least 100h after transfection,
suggesting the high stability and long-lasting activity of
the ASOs. Together, these results suggest that the
suitable time window for functional study of snoRNAs
could be 48–100h after transfection.
ASOs targeting U16 snoRNA do not impair the
expression of the host gene
Like most human snoRNAs, U16 is embedded in an intron
of its host gene encoding a ribosomal protein RPL4 (10).
The same pre-mRNA also contains another intronic
snoRNA, U18, which has three isoforms in different
introns (Figure 4A). To determine whether the ASOs tar-
geting U16 snoRNA act on the U16 coding region of the
host pre-mRNA, or on the mature U16 snoRNA, we
detected the expression of the host gene and the levels of
the neighboring U18 snoRNAs. No difference in the levels
of U18 snoRNAs was observed in cells treated with differ-
ent concentrations of ASO462026 (Figure 4B), or with dif-
ferent ASOs targeting different regions of U16 snoRNA
(Figure 4C), although U16 snoRNA was dramatically
depleted in these cases. This observation suggests that
U16 ASOs may not act on pre-mRNA. Indeed, the level
of mature RPL4 mRNA was not affected by treatment of
ASOs targeting different regions of U16 snoRNA (Figure
4D). Importantly, the level of RPL4 protein also remained
unchanged even 72h after transfection, as detected by
western analysis (Figure 4E, left panel), although in the
same cells U16 snoRNA was dramatically depleted by
ASO treatment (Figure 4E, right panel). Together, these
results indicate that the ASOs act on mature U16 snoRNA
or on pre-snoRNA after pre-mRNA splicing, or both. This
observation is consistent with a previous study, in which
degradation of trypanosome snoRNAs by over-expression
of antisense RNA also occurred at the mature snoRNA
level (26), although the RNA-mediated snoRNA degrad-
ation in trypanosomes should utilize a mechanism differ-
ent from RNaseH. In sum, our results indicate that
ASO-mediated U16 depletion does not affect expression
of the host gene.
Figure 4. Depletion of U16 snoRNA by ASO treatment does not impair the expression of the host gene. (A) Schematic depiction of the U16
snoRNA gene locus. The partial host pre-mRNA (RPL4) is shown. The gray boxes indicate intronic snoRNAs (U16 and three isoforms of U18
snoRNA) in the host gene. E2–E7, exons of RPL4 pre-mRNA. (B) ASOs targeting U16 did not affect the levels of U18 snoRNAs encoded in the
same host pre-mRNA. HeLa cells were treated for 48 h with different concentrations of ASO462026. Total RNA was prepared and subjected to
northern hybridization with probes speciﬁc to U16 and U18 snoRNAs. U4 snRNA was detected as a loading control. (C) HeLa cells were treated for
48 h with 50nM of three different ASOs targeting U16 snoRNA. Northern hybridization was performed as in (B). Ethidium bromide staining of 5S
rRNA is shown in lower panel. (D) The mRNA level of the host gene (RPL4) was not changed by U16 ASOs. Aliquots of RNAs as in (C) were
separated in a 6% polyacrylamide gel, and RPL4 mRNA was detected by northern hybridization. U3 snoRNA served as a loading control.
(E) Depletion of U16 by ASO did not alter the protein level of RPL4. HeLa cells were treated with U16 ASO (462026) for different times, as
indicated above lanes. Whole cell extracts were prepared and subjected to western analysis using an anti-RPL4 antibody (left panel). As a control for
loading, the same membrane was re-probed with an alpha-tubulin antibody. In addition, total RNA was prepared from an aliquot of test cells and
subjected to northern hybridization, using probes speciﬁc to U16. The same membrane was re-probed for U80 snoRNA, which served as a loading
control (right panel).
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using conventional transfection
As described above, ASO treatment through conventional
transfection efﬁciently and speciﬁcally depleted U16
snoRNA in human cells. To determine if this approach
can also be used to reduce other snoRNAs, we targeted
two additional snoRNAs, U80 and U81. These two C/D
box snoRNAs are encoded in different introns of the same
host non-protein-coding RNA, GAS5 (41) (Figure 5A).
Nine ASOs were synthesized for each snoRNA to cover
the entire coding regions of these RNAs (Supplementary
Figure S2A and C). Individual ASOs were transfected into
HeLa cells using Lipofectamine 2000, in the same way as
for U16 snoRNA depletion. Total RNA was prepared
48h after transfection, and subjected to northern hybrid-
ization. One active ASO for U80 and two active ASOs for
U81 were identiﬁed that caused >85% reduction of these
snoRNAs, respectively (Supplementary Figure S2B and
D), indicating that other C/D snoRNAs can also be
depleted by ASO treatment. Interestingly, the active
ASOs for both U80 and U81 snoRNAs are identiﬁed to
target snoRNA guide sequences (Supplementary Figure
S2). This observation is in agreement with the view that
snoRNA guide regions have a relatively open structure
and are ready to base-pair with the substrate RNAs.
Note that the same region of U81 snoRNA has been
targeted in a previous study using LNA or ribozyme, yet
only  60% reduction was obtained in that study (29),
suggesting the high efﬁciency of our current approach.
Although U80 and U81 are encoded in different introns
of the same pre-mRNA, depletion of U80 by its active
ASO did not affect the level of U81 snoRNA, and vice
versa (Figure 5B and C). This result is consistent with the
observation that ASOs targeting U16 snoRNA do not act
on pre-mRNA. Again, depletion of U80 snoRNA specif-
ically reduced the methylation level by  65% at the pre-
dicted position (G1612) of 28S rRNA, yet no level change
was found for methylation at site A391 of 28S rRNA that
was predicted to be guided by U81 snoRNA (Figure 5D).
Similarly, depletion of U81 speciﬁcally reduced methyla-
tion level ( 70%) at A391, but not G1612 of 28S rRNA
Figure 5. 20-MOE/chimeric ASOs can also be used to deplete other C/D box snoRNAs. (A) Gene organization of U80 and U81 snoRNAs in the
introns of GAS5 gene. Gray boxes indicate the intronic snoRNAs. The E9–E12 exons of GAS5 gene are shown in white boxes. (B) Northern
hybridization for U80 snoRNA in HeLa cells treated [(–)U80] or not treated (UTC) with 50nM of an active ASO (477457). U16 snoRNA was
detected and served as a loading control. The same blot was re-hybridized with a probe speciﬁc to U81 snoRNA. (C) U81 snoRNA was dramatically
depleted by U81-speciﬁc ASOs. HeLa cells were treated with 50nM of different active ASOs targeting U81 snoRNA [477443 for (–)U81-1, and
477444 for (–)U81-2]. Total RNA was prepared and subjected to northern hybridization, as in (B). (D) Depletion of U80 snoRNA speciﬁcally
reduced the methylation level at the predicted site in 28S rRNA (G1612). The modiﬁcation was mapped by a primer extension assay using a primer
speciﬁc to 28S rRNA. Extension products were analyzed in an 8% polyacrylamide gel, next to primer extension sequencing reactions performed with
the same primer. The Gm1612 site is indicated with an arrow, whereas a neighboring methylation site or the site guided by U81 (Am391) are marked
with arrowheads. Note that the methylation level of A391 guided by U81 snoRNA was not affected by depletion of U80 snoRNA, as determined by
primer extension using a different primer (lower panel). (E) Depletion of U81 snoRNA speciﬁcally impaired its function in guiding methylation at
site A391 of 28S rRNA. Primer extensions were performed as in (D), using different primers speciﬁc to different regions of 28S rRNA. The arrow
indicates the Am391 site guided by U81, whereas arrowheads mark a neighboring methylation or Gm1612 methylation guided by U80 snoRNA
(lower panel).
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ASO-mediated snoRNA depletion can also be used to
target other snoRNAs, and that a  80–85% reduction
of snoRNAs is sufﬁcient to cause signiﬁcant loss of
function.
ASOs are highly speciﬁc to the target snoRNAs
Many mammalian snoRNAs have isoforms with signiﬁ-
cant sequence similarities (10), thus ASOs targeting a par-
ticular snoRNA may act on other isoforms or even other
RNAs through imperfect base-pairing. To demonstrate
the speciﬁcity of the ASOs, two isoforms of a C/D box
snoRNA were chosen: U50 and U50B, which are encoded
in different introns of the same host gene (SNHG5) and
share >75% identity (Figure 6A and Supplementary
Figure S3). ASOs were screened for U50, and two active
ASOs were identiﬁed that caused >90% reduction of the
snoRNA (Figure 6B). However, no signiﬁcant change on
the level of U50B snoRNA was observed in cells treated
with these ASOs, suggesting that the ASOs are speciﬁc.
Indeed, one active ASO that causes  90% reduction of
U50 snoRNA targets the guide sequence of the snoRNA
(ASO477499, Supplementary Figure S3A), however, no
signiﬁcant reduction of U50B was observed, despite that
the guide sequence is conserved between U50 and U50B
snoRNAs, except two continuous mis-matches in the
middle and one at the 50-end (Figure 6C).
To further conﬁrm the speciﬁcity, a U50B speciﬁc ASO
was synthesized (ASO485259) that contains one
mis-match at the 50-end of the U50B snoRNA guide
region. This ASO has two mis-matches in the middle of
the duplex formed with U50 snoRNA (Figure 6C).
Consistently, transfection of the U50B ASO speciﬁcally
depleted U50B, but not U50 snoRNA, and co-transfection
of U50 and U50B ASOs depleted both snoRNAs
(Figure 6D). This result indicates that two mis-matches
in the middle of the duplex are sufﬁcient to inactivate
the ASOs. In addition, it appears that one mis-match at
the end of the duplex does not affect the ASO activity, as
shown for the U50B ASO. Interestingly, depletion of
either U50 or U50B snoRNA reduced the methylation
level at the predicted site (Cm2848 in 28S rRNA) by
 70 or  30%, respectively, however, simultaneous deple-
tion of both snoRNAs caused greater reduction ( 85%)
in methylation, indicating that both isoforms are function-
al in cells (Figure 6E). Together, these results show that
20-MOE/chimeric ASOs can deplete snoRNAs and inacti-
vate their functions in a highly speciﬁc manner.
Figure 6. ASOs are highly speciﬁc to the target snoRNAs. (A) The U50 snoRNA and its isoform U50B are encoded in different introns of SNHG5,
a non-protein coding gene. (B) Northern hybridization of U50 and U50B snoRNAs in cells treated for 48 h with 50nM of different ASOs targeting
U50 snoRNA. The active ASOs are boxed. U16 snoRNA was detected and served as a loading control. (C) Sequence comparison of ASOs targeting
the guide region of U50 and U50B snoRNAs. The snoRNA sequences are in bold. The uppercase letters in ASO sequences indicate 20-MOE/RNA
sequence, whereas lowercase letters represent DNA sequence. (D) ASOs speciﬁc to U50 (ASO477499) or U50B snoRNA (ASO485259) act speciﬁcally
on the targeted snoRNAs. HeLa cells were treated for 48 h with ASOs targeting either U50 or U50B alone (50nM), or with two ASOs targeting both
snoRNAs (30nM each). Total RNA was prepared and subjected to northern hybridization using 50-end-labeled oligonucleotides speciﬁc to U50 or
U50B, respectively. U6 snRNA was detected and served as a loading control. (E) Depletion of U50 or U50B snoRNA impairs the methylation
guided by the snoRNA. Modiﬁcation at C2848 in 28S rRNA was detected by primer extension assay using a primer speciﬁc to the C2848 region. The
targeted modiﬁcation site is indicated with an arrow, and a neighboring potential modiﬁcation site is marked with an arrowhead.
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snoRNAs
All the ﬁve snoRNAs targeted above by 20-MOE/chimeric
ASOs were successfully depleted, indicating that this
approach is not unique to individual RNAs. Since these
snoRNAs are all C/D box RNAs, next, we investigated if
another group of snoRNAs, H/ACA box RNAs that typ-
ically contain two hairpin structures, could also be
depleted in this way. Twenty ﬁve ASOs were synthesized
for U23, an H/ACA snoRNA encoded in an intron of
Nucleolin pre-mRNA (Figure 7A and Supplementary
Figure S4A). Two active ASOs were identiﬁed that
reduced the level of U23 snoRNA by 80–85%
(Figure 7B and Supplementary Figure S4B), indicating
that H/ACA type of snoRNAs can also be depleted by
conventional transfection of the ASOs. The two active
Figure 7. H/ACA box RNAs can be depleted by ASO treatment. (A) Schematic representation of partial pre-mRNA of Nucleolin. The intronic
snoRNAs U23 (H/ACA type) and U20 (C/D type) are shown in gray boxes. (B) Northern hybridization for U23 snoRNA in cells treated [(–)U23] or
not treated (UTC) with 50nM of an active ASO targeting this snoRNA (ASO483788). U16 snoRNA served as a loading control. (C) The protein
level of Nucleolin was not affected by the U23 ASO, as determined by western analysis. RPL4 protein was also probed and served as a loading
control. (D) Depletion of U23 H/ACA snoRNA impaired its function in guiding pseudouridylation at site U93 of 18S rRNA. Total RNA was
treated (+) or not treated (–) with CMC (N-cyclohexyl-N0-(2-morpholinoethyl)-carbodiimide methyl-p-toluolsulfonate), and subjected to primer
extension analysis using a primer speciﬁc to U93 region of 18S rRNA. CMC treatment causes extension to stop one nucleotide before the
pseudouridylated sites. Extension products were separated in an 8% polyacrylamide gel, next to primer extension sequencing reactions preformed
with the same primer. The targeted pseudouridylation (93) is indicated. Two neighboring pseudouridines (34 and 36) are marked with arrow-
heads. (E) An H/ACA type of scaRNA can also be degraded by ASOs. HeLa cells were treated for 48 h with two different ASOs targeting ACA45
scaRNA [462037 for (–)ACA45-1 and 462038 for (–)ACA45-2]. Total RNA was prepared and subjected to northern hybridization using a probe
speciﬁc to ACA45 scaRNA. U18 snoRNA was detected and served as a loading control. (F) Dramatic depletion of ACA45 scaRNA did not disrupt
pseudouridylation at the predicted site in U2 snRNA (37). Pseudouridines were detected as in (D), using a primer speciﬁc to U2 snRNA. Extension
products were separated in an 8% polyacrylamide gel, next to primer extension sequencing ladders generated using the same primer. The predicted
target site (37) is indicated, and other neighboring pseudouridines are marked with arrowheads. (G) Base pairing potential between ACA45
scaRNA and U2 snRNA. U2 snRNA sequence is numbered and the pseudouridines () in U2 snRNA are shown.
e13 Nucleic Acids Research, 2011,Vol. 39,No. 3 PAGE 10 OF 17ASOs target the terminal or internal loop regions in the
30-hairpin of U23 snoRNA, suggesting a higher accessibil-
ity of these regions (Supplementary Figure S4C).
As was the case for depleting C/D snoRNAs, reduction
of U23 H/ACA snoRNA by ASO treatment occurred at
the mature U23 snoRNA, since the level of another
snoRNA (U20) encoded in the same precursor was not
altered (Supplementary Figure S4B), and the protein
level of the host gene (Nucleolin) remained unchanged
(Figure 7C). These results further support the view that
ASO-mediated snoRNA depletion does not affect expres-
sion of the host genes. Next, we analyzed if a  80% re-
duction of U23 snoRNA could impair its predicted
function in guiding pseudouridylation at position U93 of
18S rRNA (10). Pseudouridylation was determined by
a primer extension assay following CMC treatment of
total RNA (37). As expected, depletion of U23 snoRNA
signiﬁcantly reduced the level of pseudouridylation at
the predicted position (U93) in 18S rRNA, as compared
with the level of neighboring pseudouridylation sites
(Figure 7D). Thus, despite of their highly structured
nature, H/ACA snoRNAs can also be depleted by
20-MOE/chimeric ASOs via conventional transfection,
and an 80% reduction of U23 snoRNA is sufﬁcient to
inactivate its function.
ASOs act on scaRNAs
In addition to snoRNAs that are accumulated in the
nucleoli, similar RNAs (scaRNAs) are also present in
the Cajal bodies where these RNAs guide nucleotide
modiﬁcation in snRNAs (42). To determine if scaRNAs
can also be targeted by ASO treatment, 16 ASOs were
synthesized for ACA45 (Supplementary Figure S5A), a
scaRNA predicted to direct pseudouridylation at site
U37 of U2 snRNA (43). Two active ASOs were identiﬁed
that target the terminal loop region of the 50-hairpin
(Supplementary Figure S5B and C). The level of ACA45
scaRNA was reduced by  85% with these two ASOs
(Figure 7E), indicating that ASOs can also be used to
deplete scaRNAs. Interestingly, no change was observed
for the level of pseudouridylation at the predicted position
(U37) in U2 snRNA (Figure 7F). This result suggests that
either the small amount of ACA45 left is sufﬁcient for full
function, or that this RNA does not have the predicted
role. Consistent with the latter possibility, we noticed that
three nucleotides (U37A38U39) of U2 snRNA
are unpaired in between the two intermolecular duplexes
formed between U2 snRNA and ACA45 RNA
(Figure 7G). This is different from the guide rule in
which two nucleotides are unpaired in the middle (44),
suggesting that ACA45 may not have the predicted
function.
The ASOs targeting a snoRNA can localize to the nucleus
As demonstrated above, ASO-mediated snoRNA deple-
tion does not occur at pre-mRNA level, rather, it takes
place most likely at mature snoRNA level. Since
snoRNAs are produced in the nucleoplasm, followed by
import into the nucleolus where they accumulate (6),
snoRNA degradation could occur either in the nucleo-
plasm or in the nucleolus, or both. To determine if
ASOs accumulate in the nucleolus, ASO462026 targeting
U16 snoRNA was transfected into HeLa cells, and the
ASOs were detected through indirect immunoﬂuorescence
using a rabbit polyclonal antibody that recognizes
phosphorothioate backbone containing oligonucleotides
in a sequence independent manner (a gift kindly
provided by Dr Erich Koller). As shown in Figure 8A,
the 20-MOE chimeric ASO is enriched and evenly
distributed in the nucleus, indicating that the ASO can
be delivered to this compartment by conventional trans-
fection. Most nucleoli lack ASO staining, however, nucle-
olar signal of ASOs can be detected in certain cases
(Figure 8A, indicated by an arrowhead). This observation
suggests that ASOs can localize in the nucleolus as well,
although to a lesser extent than in the nucleoplasm.
The large cytoplasmic speckles most likely reﬂect the
ASOs that are still present in the endosomal particles.
Note that the staining is speciﬁc to the phosphorothioate
linked oligonucleotides, since no signiﬁcant signal was
detected especially in the nucleus of cells transfected in
the same way with a conventional, unmodiﬁed oligodeox-
ynucleotide (Figure 8B). Despite the fact that a
phosphorothioate linked oligodeoxynucleotide that
contains the same sequence as ASO462026 can also be
delivered to the nucleus in this way (Figure 8C), this
oligodeoxynucleotide failed to deplete U16 snoRNA
(Figure 2E), suggesting that higher afﬁnity of ASOs to
target RNA is required for efﬁcient reduction of
snoRNAs. Together, these data imply that most likely
ASOs act on snoRNAs in the nucleoplasm. However, we
cannot completely exclude the possibility that ASOs can
trigger snoRNA degradation in the nucleolus.
snRNAs can also be degraded by ASO treatment
Next, we tested if snRNAs that are present in nuclear
speckles can also be depleted in the same way. ASOs
were synthesized for four spliceosomal U snRNAs (U1,
U2, U4 and U6) and transfected into HeLa cells. All the
tested snRNAs were successfully reduced by >85% (T. A.
Vickers et al., manuscript in preparation). As exempliﬁed
for U1 snRNA, ASO treatment reduced the level
of this snRNA by  90%, as determined using northern
hybridization (Figure 9A). As expected, depletion of
U1 snRNA impaired pre-mRNA splicing, resulting in re-
duction of mature mRNA and accumulation of
pre-mRNA, as determined by qRT-PCR for a reporter
minigene, using different probe-primer sets for mature or
pre-mRNA (Figure 9B and C). This result indicates that
ASOs can also successfully target ncRNAs in the
nucleoplasm.
Multiple snoRNAs can be simultaneously depleted by
ASO treatment
Based on the study performed in yeast, genetic deletion of
most guide snoRNAs individually has no obvious effects
on cell growth, whereas combined knockout of several
snoRNAs targeting modiﬁcations in a particular domain
of the rRNA can signiﬁcantly impair ribosome biogenesis
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several snoRNAs need to be depleted at the same time in
order to study the function of modiﬁcations. Thus, we
determined if multiple snoRNAs could be depleted simul-
taneously in human cells by co-transfection of a set of
ASOs targeting different RNAs. Five snoRNAs, including
four C/D snoRNAs (U16, U50, U80, U81) and one H/
ACA snoRNA (U23), were targeted by co-transfection of
ﬁve active ASOs speciﬁc to these RNAs, with 10nM or
15nM ﬁnal concentrations of each ASO. The four C/D
snoRNAs were all dramatically depleted (>85% reduc-
tion), however, the H/ACA snoRNA (U23) was only
moderately reduced at these ASO concentrations
(Figure 10A), consistent with the fact the H/ACA RNAs
have a more structured feature. This result suggests that
ASO concentration for the H/ACA snoRNA should be
higher than that for C/D snoRNAs, in order to obtain
signiﬁcant reduction.
Next, we tested the effects of different ASO concentra-
tions on depleting U23 snoRNA, in combination with 10
or 8nM ASOs for C/D snoRNAs. Indeed, U23 snoRNA
was reduced by >85% at 20–40nM ASO concentrations,
and the four C/D snoRNAs were also dramatically
depleted (>90%) at 10 or 8nM concentration of ASOs
(Figure 10B). These observations indicate that for
multiple depletions, different snoRNAs may require
Figure 8. ASOs are enriched in the nucleus after conventional transfection. HeLa cells were transfected with either ASO462026 (A), or a conven-
tional DNA oligonucleotide [XL011, (B)], or the DNA oligonucleotide linked with phosphorothioate backbone, as used in Figure 2E (C). After
incubation at 37 C for 6 h, cells were ﬁxed, stained with antibodies against the phosphorothioate linked oligonucleotides (green) and Nucleolin (red),
a nucleolar marker protein, as described in ‘Materials and Methods’ section. The nucleus was stained with DAPI (blue). The arrow indicates
cytoplasmic ASO particles, whereas the arrowhead marks the nucleolus with ASO staining. The scale bars: 10mm.
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for H/ACA snoRNAs. We note that cells grew normally
even at the highest ASO concentration (total 80nM), sug-
gesting that there was no toxicity under these conditions.
In addition, we also noticed that lower cell conﬂuency for
transfection could lead to a greater reduction. For
example, at 10nM ASO concentration,  85% reduction
was obtained for U16 snoRNA with  50% conﬂuency of
starting cells (Figure 10A), whereas >95% reduction was
achieved with  30% conﬂuency (Figure 10B), suggesting
that cell conﬂuency affects transfection efﬁciency, which in
turn affects depletion effects. All together, these results
indicate that multiple snoRNAs can be simultaneously
depleted in human cells by ASOs using conventional
transfection.
snoRNAs can be depleted in vivo by systematic
administration of the ASOs
The results described above indicate that the 20-MOE/
Chimeric ASOs are highly suitable and convenient for
functional study of the nuclear ncRNAs, by conventional
transfection. These ﬁndings suggest that the ASOs may
also operate in animals, such as mice, to manipulate the
level of snoRNAs. To demonstrate this possibility, we ﬁrst
targeted snoRNAs in different mouse cells in vitro,t o
ensure the activity of the ASOs. Mouse U16 and U50
snoRNAs were targeted, since a human U16 snoRNA
ASO (462026) and a U50 snoRNA ASO (477499) have
perfect complementarities to the mouse snoRNAs, re-
spectively. The two mouse snoRNAs were reduced by
>80% in b.ENDs cells (Figure 11A) or by >95% in
primary hepatocytes (Figure 11B), using conventional
transfection of the corresponding ASOs. Like the case in
human cells, the two snoRNAs can also be simultaneously
depleted in mouse cells by co-transfection of the ASOs,
indicating that ASO-mediated snoRNA depletion also
operates in mouse cells.
Next, ASO effects on snoRNA depletion in vivo were
determined through systematic administration of a single
dose of 100mg/kg ASOs in 7-week-old male BALB/c mice
(n = 5). Animals were sacriﬁced 72h after subcutaneous
injection and total RNA was prepared from mouse liver.
As detected by northern hybridization, U16 or U50
snoRNA was almost completely depleted in liver of mice
administrated with the corresponding ASOs (Figure 11C).
No signiﬁcant difference in depletion efﬁciency was
observed among the ﬁve animals within each group. As
controls, injection of either saline or a control ASO
(ISIS141923) has no effect on the levels of these
snoRNAs, indicating the speciﬁcity of the ASOs and
that ASOs can be delivered into liver and act in the
nucleus. Importantly, depletion of these snoRNAs also
caused speciﬁc reduction ( 50%) in the levels of corres-
ponding rRNA methylation guided by these snoRNAs, as
determined by a primer extension assay (Figure 11D), con-
sistent with the in vitro results. In addition, moderate re-
duction ( 40–60%) was also observed for U16 and U50
snoRNAs in kidney and white fat (WAT), but no signiﬁ-
cant depletion was found in heart, spleen and muscle
(Figure 11E and data not shown), suggesting that ASOs
Figure 9. Spliceosomal snRNAs can be depleted by ASO treatment
using conventional transfection. (A) HeLa cells were treated for 48h
with 50nM of a U1 speciﬁc ASO (469508). Total RNA was prepared
and U1 snRNA was detected by northern hybridization. U6 snRNA
was determined and served as a loading control. UTC, untreated cells.
(B) ASO-mediated U1 depletion impaired pre-mRNA splicing. The
levels of mature mRNA and un-spliced pre-mRNA of a mini-reporter
gene (derived from SMN2 gene, exon 6–8) were determined by
qRT-PCR, using primer probe sets speciﬁc to spliced or un-spliced
RNAs. (C) Positions of primer probe sets used in (B). Exons (E) are
shown in boxes. Primer positions are indicated using arrows. The probe
position in exon 6 is marked with a bar.
Figure 10. Multiple snoRNAs can be depleted simultaneously.
(A) HeLa cells ( 50% conﬂuency) were transfected with ﬁve different
ASOs targeting C/D snoRNAs U16, U50, U80, U81 and H/ACA
snoRNA U23 (ASOs 462026, 477499, 477457, 477443 and 483788, re-
spectively), at 10nM (5 10nM) or 15nM (5 15nM) ﬁnal concentra-
tion of each ASO. Total RNA was prepared 24 h after transfection and
subjected to northern hybridization for the levels of these snoRNAs.
U17 snoRNA was detected and served as a loading control. Note that
U80 snoRNA was detected twice to separate from U50 snoRNA.
(B) HeLa cells ( 30% conﬂuency) were transfected with the ﬁve
ASOs as indicated in (A), but with different ASO concentrations.
4 10 or 4 8, the ﬁnal concentrations of the four ASOs targeting
the four C/D snoRNAs was either 10 or 8nM, respectively. The con-
centrations of the U23 ASO were 20, 30 or 40nM (+20,+30 and+40).
Northern hybridization was performed as in (A).
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these results indicate that snoRNAs can be dramatically
depleted in mice by systematic administration of the
20-MOE/chimeric ASOs.
DISCUSSION
Using conventional transfection, here we showed that the
20-MOE/chimeric ASOs can efﬁciently degrade all tested
ncRNAs that are present in different sub-nuclear struc-
tures, including nucleolus, Cajal bodies and nuclear
speckles. Depletion was achieved in different human
and mouse cells, using different transfection reagents.
Reduction of snoRNAs signiﬁcantly reduced the level of
nucleotide modiﬁcation in endogenous rRNAs guided by
the snoRNAs. Surprisingly and attractively, ASOs target-
ing intronic snoRNAs do not affect expression of the host
genes, thus minimizing unexpected effects for functional
studies. Importantly, snoRNAs can also be depleted
in vivo by subcutaneous injection of the 20-MOE/
chimeric ASOs, making ASOs a powerful approach to
functionalize small ncRNAs, and potentially as drugs to
target disease-causing ncRNAs.
Figure 11. snoRNAs can be depleted in mice by systematic administration of ASOs. ASO477499 (for U50) and ASO462026 (for U16) were trans-
fected individually (50nM) or together (35nM each) into bEND.3 cells (A) or mouse primary hepatocytes (B) using Lipofectamine 2000, and total
RNA was prepared 24 h after transfection. The levels of U16 and U50 were determined by northern hybridization. U2 snRNA was detected and
served as a loading control. (C)2 0-MOE/chimeric ASOs can deplete snoRNAs in vivo. Seven-week-old mice (n=5) were subcutaneously injected with
100mg/kg of ASO462026 (U16), ASO477499 (U50) or ASO141923 (Control), and sacriﬁced 72 h later. Total RNA was prepared from liver and
subjected to northern hybridization to determine the levels of U16 and U50 snoRNAs. U2 snRNA was used as a loading control. Different lanes
represent total liver RNA prepared from different mouse. Saline, total liver RNA prepared from mouse injected with saline. (D) Reduction of
snoRNAs in vivo decreased the levels of targeted rRNA methylation. Total RNA used in (C) was pooled for each group, and subjected to primer
extension analysis to detect rRNA methylation at positions targeted by U16 snoRNA (Am485 in 18S rRNA) or U50 snoRNA (Cm2613 in 28S
rRNA). Open arrows indicate the reduced methylation level that is reﬂected by decreased signal strength at 0.05mM dNTP concentration, as
compared with control samples. The modiﬁed positions are numbered with mouse rRNA. The equivalent positions in human rRNAs are shown in
parentheses. (E) Moderate reduction of snoRNAs can also be observed in other tissues. Total RNA was prepared from different tissues of the
animals used in (C), pooled for each group, and analyzed by northern hybridization, as in (C). Ethidium bromide staining of 5S rRNA is shown.
WAT, white adipose tissue.
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a full RNA screening approach. The candidate target
regions of snoRNAs can be proposed based on our data
and published information. For four of the ﬁve tested C/D
snoRNAs, the most potent ASOs were found to target the
guide regions (ASO 477457 for U80 snoRNA, ASO477444
for U81 snoRNA, ASO477499 for U50 snoRNA and
ASO485259 for U50B RNA). This observation is consist-
ent with the fact that C/D snoRNAs contain long, con-
tinuous antisense guide sequence (12–24nt) that base-pair
with the substrate RNAs (47), therefore the guide se-
quences are more likely to be accessible to the ASOs.
However, this is not always the case, as shown for the
U16 snoRNA, for which the most potent ASOs target
snoRNA regions outside the guide sequence. Thus, it is
reasonable to target the guide region(s) of C/D snoRNAs
as a ﬁrst attempt. However, screening for active sites may
be required if no success with the guide region(s). For H/
ACA RNAs, which typically contain two hairpin struc-
tures, the most active sites for ASO target were found to
be the terminal loop regions, as well as the internal loop
where the guide sequence may be present.
The observation that at least ﬁve snoRNAs could be
depleted simultaneously is interesting. Co-transfection of
ﬁve different ASOs caused dramatic reduction of all the
ﬁve targeted snoRNAs. This ﬁnding suggests that these
ASOs do not strongly compete for the recruitment of
RNaseH, or that RNaseH is not a limiting factor under
these experimental conditions. This feature makes the
ASOs a very convenient and efﬁcient approach to
analyze the biological roles of multiple modiﬁcations
in a particular domain of rRNAs or snRNAs, since in
many cases deletion of a single modiﬁcation had no
effect, yet cumulative or synergistic effects could be
observed when several modiﬁcations were co-deleted
from rRNA, e.g. (33,45–46).
During this work, a report published recently that
showed that ASO-mediated snoRNA reduction (>80%)
in human cells was achieved using a specialized device,
but not by conventional transfection (30). Here we show
clearly that 20-MOE/chimeric ASOs can efﬁciently deplete
small ncRNAs present in different sub-nuclear structures
by conventional transfection in different human and
mouse cells, even with different transfection reagents.
The different observations for conventional transfection
may step from the fact that, in our study, the most
active ASOs were identiﬁed by full RNA screening,
whereas in the previous study the sequences of ASOs
were not optimized. Nevertheless, our results indicate
that different nuclear ncRNAs can be depleted by con-
venient, conventional transfection to a level that is sufﬁ-
cient to cause functional loss.
Consistent with previous studies (29,30), here we also
found that siRNA does not act on snoRNAs, inferring
that RISC is not active in the nucleus of human cells.
To support an RNaseH-based mechanism, transfection
of MOE/RNA oligoes did not reduce the level of target
snoRNA. Additionally, a DNA oligonucleotide with the
same sequence as a most potent ASO only caused a
moderate reduction of the target snoRNA, indicating
the advantages of 20-MOE/chimeric ASOs in depleting
snoRNAs. Indeed, we showed that U81 snoRNA could
be dramatically depleted by MOE/chimeric ASOs ( 85%
reduction), accompanied by a clear reduction in the
methylation level at the targeted site of rRNA
(Figure 5). This same snoRNA has been targeted by dif-
ferent approaches in a previous study (29), including a
LNA that has a sequence almost identical to an active
ASO identiﬁed in this study (477444). The snoRNA level
could only be reduced by  60% using the LNA, and no
functional loss of the U81 snoRNA has been observed in
the previous study (29). The difference in knockdown
efﬁciency of 20-MOE/chimeric ASO and LNA likely
stems from the higher afﬁnity of MOE chimeric ASOs
and the more thorough screening we performed.
Different transfection efﬁciencies may also affect the
activity. Indeed, lower depletion efﬁciency of snoRNAs
was observed when higher conﬂuency of starting cells
was used (Figure 10 and data not shown), suggesting
that transfection efﬁciency signiﬁcantly affects snoRNA
depletion. Thus we optimized the transfection by
starting at  30% conﬂuency, with which >85% reduction
of snoRNAs could often be achieved.
ASOs targeting snoRNAs have the ability to base-pair
with snoRNA precursors, thus it is possible to trigger deg-
radation of pre-snoRNAs. However, we found that the
20-MOE/chimeric ASOs are capable to deplete the
intronic snoRNAs without affecting the expression of
the host genes. These observations indicate that the
ASOs targeting snoRNAs do not act on pre-mRNA.
The different effects of ASOs on depleting mature
snoRNAs and pre-mRNAs may stem from different
accessibilities of these molecules, due to differences in
the structures and compositions of pre-mRNA–protein
complex and the mature snoRNP complex, thus leading
to differential accessibility to ASOs. Indeed, mature
snoRNPs contain only the four core proteins, whereas
additional proteins are required for snoRNA maturation
and snoRNP assembly. For example, Naf1 and Shq1 are
required for H/ACA snoRNP assembly but are absent in
mature snoRNP (48–50). It has been shown that Naf1
interacts with pre-snoRNP co-transcriptionally, and
after splicing, this protein is replaced by a H/ACA
snoRNP core protein, Gar1 (51–53). Thus, compositional
exchange of the RNPs may lead to structural changes
between pre-snoRNP and mature snoRNP complexes.
To support this view, re-structuring of snoRNP complex
or core proteins has been found for C/D snoRNPs, and it
was proposed that this restructuring could reﬂect the con-
version from pre-snoRNP to mature snoRNP complex
(54). These ﬁndings may explain why pre-mRNA cannot
be targeted by the snoRNA ASOs. However, other factors
can also contribute to the difference, such as different
cellular localizations and half-lives between pre-mRNA
and mature snoRNAs. Despite of the uncertainty of the
mechanisms, it is clear that ASOs can speciﬁcally target
intronic snoRNAs, without affecting expression of the
host genes. This feature makes ASOs highly suitable for
functional studies of mammalian nuclear ncRNAs.
Small ncRNAs have already been implicated in human
diseases, and more links between impaired expression/
function of ncRNAs and diseases are to be identiﬁed.
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nuclear ncRNAs are limited, even in vitro. In this study,
we showed that snoRNAs can be dramatically depleted in
mice by systematic administration of ASOs. Greatest de-
pletion was achieved in mouse liver, and moderate deple-
tion was found in kidney and white fat. Since only a single
dose was used in this experiment, it is conceivable to
achieve higher depletion in other tissues, by multi-dose
treatment or by different delivery approaches. Thus, the
20-MOE/chimeric ASOs have great potential to develop
drugs against disease-causing ncRNAs that are difﬁcult
to be depleted by other means, such as siRNAs.
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